Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer (NSCLC) (NCT01407822). Herein, we report the final results. Recruited patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Wen-Zhao, Yan, Hong-Hong, Chen, Ke-Neng, Chen, Chun, Gu, Chun-Dong, Wang, Jun, Yang, Xue-Ning, Mao, Wei-Min, Wang, Qun, Qiao, Gui-Bin, Cheng, Ying, Xu, Lin, Wang, Chang-Li, Chen, Ming-Wei, Kang, Xiao-Zheng, Yan, Wan-Pu, Liao, Ri-Qiang, Yang, Jin-Ji, Zhang, Xu-Chao, Liu, Si-Yang, Zhou, Qing, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950485/
https://www.ncbi.nlm.nih.gov/pubmed/36823150
http://dx.doi.org/10.1038/s41392-022-01286-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950485/
https://www.ncbi.nlm.nih.gov/pubmed/36823150
http://dx.doi.org/10.1038/s41392-022-01286-3

Ejemplares similares